Author

Alan D. Langerak

Observed names: A. D. Langerak, Alan Langerak

Institutions: City of Hope, Arizona Oncology

Observed institutions: Amgen (United States), Thomas Jefferson University, Sidney Kimmel Cancer Center, City of Hope, Saint Alphonsus Regional Medical Center, Arizona Oncology

OpenAlex ID: A5081386100

Panitumumab Monotherapy in Patients with Metastatic Colorectal Cancer and Cetuximab Infusion Reactions: A Series of Four Case Reports

2009 · Alan Langerak, George River, et al. · Clinical Colorectal Cancer · 28

Chemotherapy Regimens and Cancer Care

2001 · Alan D. Langerak · CRC Press eBooks · 20

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline

2026 · Lisa K. Hicks, Hans J. Messersmith, et al. · Journal of Clinical Oncology · 9

Bendamustine with rituximab, etoposide and carboplatin (T(R) EC ) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial

2018 · Lihua E. Budde, David Wu, et al. · British Journal of Haematology · 9

Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer (mCRC) patients (pts) intolerant to cetuximab

2007 · A. D. Langerak, E. Mitchell, et al. · Journal of Clinical Oncology · 7

Transforming growth factor-?1

1999 · Alan D. Langerak, Harinder S. Garewal · Cancer · 3

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1

2026 · Rahul Banerjee, Matthew C. Cheung, et al. · Journal of Clinical Oncology · 1

A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma.

2015 · L. Elizabeth Budde, Daniel B. Martin, et al. · Journal of Clinical Oncology

Works count: 8

Citation count: 77

H-index: 5

I10-index: 2